Eduardo Dunayevich, MD

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...

Morgan Bron, Susan D. Mathias, Donald E. Stull, et al

Article

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

June 20, 2013

In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of...

Susan L. McElroy, Eduardo Dunayevich, Anna I. Guerdjikova, et al

Original Research

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

February 9, 2010

Stephen R. Marder, Mary Anne Dellva, Eduardo Dunayevich, et al

Original Research

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

August 15, 2007

Fangyi Zhao, Mary Anne Dellva, Jennie G. Jacobson, et al

Original Research

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians

April 16, 2007

Christer Allgulander, Eduardo Dunayevich, James M. Russell, et al

Letter to the Editor

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

January 15, 2005

James L. Karagianis, Eduardo Dunayevich

Original Research

Twelve-Month Outcome in Bipolar Patients With and Without Personality Disorders

July 31, 2000

Paul E. Keck, Jr., Susan L. McElroy, Stephen M. Strakowski, et al

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

Twelve-Month Outcome in Bipolar Patients With and Without Personality Disorders

ELSEWHERE:

FOLLOW US:

Eduardo Dunayevich, MD

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

Twelve-Month Outcome in Bipolar Patients With and Without Personality Disorders

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles